Taiwan's Medigen set to acquire Pacgen
This article was originally published in Scrip
Executive Summary
Pacgen Biopharmaceuticals and the Taiwanese firm Medigen Biotechnology have signed a letter of intent to merge, in a deal to be completed next February. Current Medigen shareholders would own a majority of the as yet unnamed combined operation.